VERY HIGH ACCURACY
Results from the lab and animal trials have shown that GlucoSet sensors have high accuracy, in particular in the low blood glucose ranges, which is important to enable tight glucose control.
SUPERIOR PLATFORM
The GlucoSet sensor is a biosensor with a hydrogel matrix incorporated with a glucose binding molecule. The gel contracts at rising glucose concentrations as a consequence of glucose-induced cross-binding of the glucose binding molecules. The hydrogel is fabricated at the tip of an optical fiber, and the whole sensor is covered with a semipermeable coating. The diameter of the gel is measured by an interferometric technique (illustration on the right). Changes in glucose concentration cause the volume of the gel to change, causing its diameter to change accordingly.
SCALABLE TECHNOLOGY
The GlucoSet technology was designed from the start to be manufactured in small volumes in the lab for R&D just as well as on an industrial scale for use in clinics. GlucoSet holds patents for the manufacturing process.
TESTED IN HUMANS
The technology has been tested in humans, and further tests are planned.
STRONG IPR
GlucoSet holds several patents for different aspects of the sensor technology platform in key markets. The IP portfolio is in continual development.
References
- Skjaervold, Nils K., et al. "Continuous Measurement of Blood Glucose." Anesthesiology 114.1 (2011): 1.
- Inzucchi, Silvio E., and Mikhail Kosiborod. "Continuous glucose monitoring during critical care." Anesthesiology 114.1 (2011): 18-19.